Brussels - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, UCB SA/NV ('UCB' or the 'Company') (Euronext Brussels: UCB) hereby discloses certain information in relation to its Share Repurchase Program 2026.
Under this program, UCB has requested a financial intermediary to repurchase up to 500,000 UCB shares on its behalf under the terms of a discretionary mandate agreement effective as from 16 March 2026 and with initial validity until the later of 30 June 2026, and, to the extent authorized by the extraordinary shareholders' meeting of April 2026, 30 September 2026, to cover current and future obligations under UCB's Long Term Incentive Plans for its personnel.
Contact:
Antje Witte
Tel: +32 2 559 94 14
Email: [email protected]
Yvonne Naughton
Tel: +44-7566790245
Email: [email protected]
Sahar Yazdian
Tel: +32.2.559.9137
Email: [email protected]
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9,000 people in approximately 40 countries, the company generated revenue of EUR7.7 billion in 2025. UCB is listed on Euronext Brussels (symbol: UCB).
(C) 2026 Electronic News Publishing, source ENP Newswire